The risk assessment of drugs in pregnancy can be improved through better kn
owledge and interpretation of significant experimental findings. Embryo-fet
al effects can be considered as the endpoint of importance, after excluding
that their occurrence is related to maternal toxicity. If embryo-fetal tox
ic effects occur in the presence of maternal toxicity, the dam influence sh
ould be clearly assessed, and can be taken into account in the determinatio
n of a safety margin. A determination of the lowest developmental toxic dos
e, if any, apart from any maternal toxicity, should be made. With positive
animal developmental findings, interpretation should take into account vari
ous parameters including the incidence and the severity of the embryo-fetal
insult, interspecies reproducibility, the level of exposure, metabolic pat
hways, and the results of possible mechanistic investigations. Hierarchizat
ion of the experimental findings should take into account all these paramet
ers together to provide support for the risk assessment in humans. (C) 2000
Elsevier Science Inc. All rights reserved.